Table 1.
Patient characteristics of discovery and validation cohort
| Discovery cohort | Validation cohort | |||||
|---|---|---|---|---|---|---|
| Total | Male | Female | Total | Male | Female | |
| Count | 148 | 97/148 (66%) | 51/148 (34%) | 184 | 128/184 (70%) | 56/184 (30%) |
|
Age (years), M (±SD) |
68 (±12) | 69 (±12) | 67 (±11) | 63 (±13) | 63 (±13) | 62 (±13) |
| BMI, M (±SD) | 28 (±5) | 28 (±4) | 29 (±6) | 27 (±4) | 27 (±4) | 27 (±4) |
|
Hospitalization period (days), M (±SD) |
9 (±6) | 10 (±7) | 9 (±6) | 6 (±4) | 6 (±4) | 6 (±3) |
| ICU admission | 41/148 (28%) | 30/97 (31%) | 11/51 (22%) | 77/184 (42%) | 58/128 (45%) | 19/56 (34%) |
| Mortality | 44/148 (30%) | 33/97 (34%) | 11/51 (22%) | 27/184 (15%) | 18/128 (14%) | 9/56 (16%) |
|
IL‐38 (pg/ml), M (±SD) |
125 (421) | 126 (411) | 124 (444) | 137 (377) | 121 (301) | 173 (511) |
| Maximum | 3735 | 3735 | 3035 | 3297 | 3297 | 1096 |
| Minimum (detection limit) | 15.6 | 15.6 | 15.6 | 15.6 | 15.6 | 15.6 |
| Detectable | 46/148 (32%) | 30/97 (31%) | 16/51 (31%) | 61/184 (33%) | 42/128 (33%) | 19/56 (34%) |
| Undetectable | 101/148 (68%) | 67/97 (69%) | 35/51 (69%) | 123/184 (67%) | 86/128 (67%) | 37/56 (66%) |
Abbreviations: BMI, body mass index; ICU, intensive care unit; IL, interleukin.